Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided maintenance therapy after autologous stem cell transplantation for multiple myeloma
ChiCTR2000031516Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- May 2020
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib and lenalidomide in multiple myeloma (MM), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Overall survival. Planned start May 2020; status: not yet recruiting.
02
Drugs
bortezomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000031516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031516.